NCI (01336): Zhang Xiufen's Director Appointment Pending Regulatory Approval

Stock News2025-12-24

NCI (01336) announced that the proposal regarding the election of directors for the ninth board of directors has been formally approved by shareholders. According to relevant Chinese laws and regulations, Ms. Zhang Xiufen's director appointment is still subject to regulatory approval. Until her qualification is approved, Mr. Ma Yaotian, the company's independent non-executive director, will continue to perform his duties in compliance with laws, regulations, and the company's articles of association.

Ms. Zhang Xiufen will sign a corresponding service agreement with the company, and her term will commence upon regulatory approval of her directorship and last until the end of the ninth board's tenure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment